Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Safinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 6/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Safinamide SCHEMBL31174565 | 1.00 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL18805068 | 1.00 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL29358109 | 1.00 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL69350 | 1.00 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL194169 | 1.00 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL1665715 | 0.96 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL29358128 | 0.96 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL2938424 | 0.96 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL1665721 | 0.96 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL1665414 | 0.96 | MAOB (0.92) | MAOBMAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | claimed |
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | claimed |
| CN-104523668-B | High-purity 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides and use thereof | 纽朗制药有限公司 | 2020-06-09 | — | — | CN | claimed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | claimed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | claimed |
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| EP-2029130-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARM SPA (IT) | 2015-08-19 | — | — | EP | claimed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | claimed |
| US-8846763-B2 | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-09-30 | — | — | US | claimed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | claimed |
| EP-1045830-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARM SPA (IT) | 2003-04-23 | — | — | EP | claimed |
| US-6306903-B1 | ANALGESICS FOR ALLEVIATION OF CHRONIC AND NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-23 | — | — | US | claimed |
| EP-1045830-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-25 | — | — | EP | claimed |
| WO-1999035125-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
| EP-0400495-B1 | N-phenylalkyl substituted alpha-amino carboxamide derivatives and process for their preparation. | ERBA CARLO SPA (IT) | 1993-11-03 | — | — | EP | claimed |
| US-5236957-A | Antiepileptic agents | FARMITALIA CARLO ERBA SRL (IT) | 1993-08-17 | — | — | US | claimed |
| EP-0426816-A1 | N-PHENYLALKYL SUBSTITUTED $g(a)-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-05-15 | — | — | EP | claimed |
| EP-0400495-A1 | N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-12-05 | — | — | EP | claimed |
| WO-1990014334-A1 | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | MAOB 4259/4885MAOA 4437/4885SCN9A 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.